Three antibodies from Atlas Antibodies in Immuno Oncology - Hodgkin lymphoma research

February, 2022 (Department of Pathology and Medical Biology, University Medical Center Groningen, Netherlands)

Immuno Oncology: Hodgkin lymphoma

CD4+ cells are a type of T-cell in the immune system that play a critical role in the pathogenesis of classical Hodgkin lymphoma (cHL), a cancer of the lymphatic system.

Veldman et al. (2020) aimed to further characterize the CD4+ T-cells and the protein expression profile in the cHL tumor microenvironment; to this end, immunohistochemistry was performed on 19 cHL tissue samples.

Three antibodies from Atlas Antibodies were used in the study:
anti-TOX2 (HPA049900)
anti-NFIA (HPA006111)
anti-CTTN (HPA057242)

Results suggest that targeting some of these proteins (TOX2 in particular) might provide interesting opportunities for immunotherapy in patients with cHL.

Read the full article:

Image credit: Veldman et al. OncoImmunology 2020